273 related articles for article (PubMed ID: 11683961)
1. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
[TBL] [Abstract][Full Text] [Related]
2. Alternative exon usage in the 3' region of a single gene generates glycosylphosphatidylinositol-anchored and transmembrane forms of rat decay-accelerating factor.
Miwa T; Okada N; Okada H
Immunogenetics; 2000 Feb; 51(2):129-37. PubMed ID: 10663575
[TBL] [Abstract][Full Text] [Related]
3. Characterization of mouse DAF on transfectant cells using monoclonal antibodies which recognize different epitopes.
Ohta R; Imai M; Fukuoka Y; Miwa T; Okada N; Okada H
Microbiol Immunol; 1999; 43(11):1045-56. PubMed ID: 10609614
[TBL] [Abstract][Full Text] [Related]
4. Tissue distribution of products of the mouse decay-accelerating factor (DAF) genes. Exploitation of a Daf1 knock-out mouse and site-specific monoclonal antibodies.
Lin F; Fukuoka Y; Spicer A; Ohta R; Okada N; Harris CL; Emancipator SN; Medof ME
Immunology; 2001 Oct; 104(2):215-25. PubMed ID: 11683962
[TBL] [Abstract][Full Text] [Related]
5. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.
Sogabe H; Nangaku M; Ishibashi Y; Wada T; Fujita T; Sun X; Miwa T; Madaio MP; Song WC
J Immunol; 2001 Sep; 167(5):2791-7. PubMed ID: 11509624
[TBL] [Abstract][Full Text] [Related]
6. Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting.
Sun X; Funk CD; Deng C; Sahu A; Lambris JD; Song WC
Proc Natl Acad Sci U S A; 1999 Jan; 96(2):628-33. PubMed ID: 9892684
[TBL] [Abstract][Full Text] [Related]
7. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
Lublin DM; Coyne KE
J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
[TBL] [Abstract][Full Text] [Related]
8. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack.
Miwa T; Zhou L; Hilliard B; Molina H; Song WC
Blood; 2002 May; 99(10):3707-16. PubMed ID: 11986227
[TBL] [Abstract][Full Text] [Related]
9. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form.
Song WC; Deng C; Raszmann K; Moore R; Newbold R; McLachlan JA; Negishi M
J Immunol; 1996 Nov; 157(9):4166-72. PubMed ID: 8892654
[TBL] [Abstract][Full Text] [Related]
10. Retrovirus-mediated over-expression of decay-accelerating factor rescues Crry-deficient erythrocytes from acute alternative pathway complement attack.
Kim DD; Miwa T; Song WC
J Immunol; 2006 Oct; 177(8):5558-66. PubMed ID: 17015743
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).
Qian YM; Haino M; Kelly K; Song WC
Immunology; 1999 Oct; 98(2):303-11. PubMed ID: 10540231
[TBL] [Abstract][Full Text] [Related]
12. Molecular and functional analysis of mouse decay accelerating factor (CD55).
Harris CL; Rushmere NK; Morgan BP
Biochem J; 1999 Aug; 341 ( Pt 3)(Pt 3):821-9. PubMed ID: 10417349
[TBL] [Abstract][Full Text] [Related]
13. Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.
Ahmad SR; Lidington EA; Ohta R; Okada N; Robson MG; Davies KA; Leitges M; Harris CL; Haskard DO; Mason JC
Immunology; 2003 Oct; 110(2):258-68. PubMed ID: 14511240
[TBL] [Abstract][Full Text] [Related]
14. Complement-dependent enhancement of CD8+ T cell immunity to lymphocytic choriomeningitis virus infection in decay-accelerating factor-deficient mice.
Fang C; Miwa T; Shen H; Song WC
J Immunol; 2007 Sep; 179(5):3178-86. PubMed ID: 17709533
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction through decay-accelerating factor. Interaction of glycosyl-phosphatidylinositol anchor and protein tyrosine kinases p56lck and p59fyn 1.
Shenoy-Scaria AM; Kwong J; Fujita T; Olszowy MW; Shaw AS; Lublin DM
J Immunol; 1992 Dec; 149(11):3535-41. PubMed ID: 1385527
[TBL] [Abstract][Full Text] [Related]
17. Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Harris CL; Spiller OB; Morgan BP
Immunology; 2000 Aug; 100(4):462-70. PubMed ID: 10929073
[TBL] [Abstract][Full Text] [Related]
18. Signal transduction via a protein associated with a glycosylphosphatidylinositol-anchored protein, decay-accelerating factor (DAF/CD55).
Kuraya M; Fujita T
Int Immunol; 1998 Apr; 10(4):473-80. PubMed ID: 9620603
[TBL] [Abstract][Full Text] [Related]
19. Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
Hanna S; Spiller O; Linton SM; Mead RJ; Morgan B
Eur J Immunol; 2002 Feb; 32(2):502-9. PubMed ID: 11828367
[TBL] [Abstract][Full Text] [Related]
20. Glycosyl-phosphatidylinositol reanchoring unmasks distinct antigen-presenting pathways for CD1b and CD1c.
Geho DH; Fayen JD; Jackman RM; Moody DB; Porcelli SA; Tykocinski ML
J Immunol; 2000 Aug; 165(3):1272-7. PubMed ID: 10903726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
